Christopher S. King

9.2k total citations · 4 hit papers
128 papers, 5.7k citations indexed

About

Christopher S. King is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Christopher S. King has authored 128 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Pulmonary and Respiratory Medicine, 34 papers in Surgery and 22 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Christopher S. King's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (47 papers), Pulmonary Hypertension Research and Treatments (38 papers) and Transplantation: Methods and Outcomes (19 papers). Christopher S. King is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (47 papers), Pulmonary Hypertension Research and Treatments (38 papers) and Transplantation: Methods and Outcomes (19 papers). Christopher S. King collaborates with scholars based in United States, France and Canada. Christopher S. King's co-authors include Lisa K. Moores, Scott C. Woller, Scott M. Stevens, Janine Vintch, Clive Kearon, Henri Bounameaux, Menno V. Huisman, Namita Sood, Elie A. Akl and Joseph Ornelas and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Christopher S. King

107 papers receiving 5.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Antithrombotic Therapy for VTE Disease

2016 3.2k citations Christopher S. King, Scott M. Stevens et al. CHEST Journal profile →
Antithrombotic Therapy for VTE Disease

2021 487 citations Scott M. Stevens, Scott C. Woller et al. CHEST Journal profile →
Executive Summary

2021 228 citations Scott M. Stevens, Scott C. Woller et al. CHEST Journal profile →
Antithrombotic Therapy for VTE Disease

2024 37 citations Scott M. Stevens, Scott C. Woller et al. CHEST Journal profile →

Peers

Countries citing papers authored by Christopher S. King

Since Specialization

Citations

This map shows the geographic impact of Christopher S. King's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher S. King with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher S. King more than expected).

Fields of papers citing papers by Christopher S. King

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher S. King. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher S. King. The network helps show where Christopher S. King may publish in the future.

Co-authorship network of co-authors of Christopher S. King

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher S. King. A scholar is included among the top collaborators of Christopher S. King based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher S. King. Christopher S. King is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	SARS-CoV-2 Immune Complex–Mediated Neutrophil Activation 2025 ·Open Forum Infectious Diseases ·(unknown), (unknown), Heather Teague, Marcos J. Ramos-Benítez, (unknown), Xin Tian, Robert Reger, Peter D. Burbelo, (unknown), Yogendra Kanthi, Jeffrey I. Cohen, (unknown), Anthony F. Suffredini, Christopher S. King, Steven D. Nathan, Richard Childs, Daniel S. Chertow, Jeffrey R. Strich	2
2	Derivation of a simple risk calculator for predicting clinical worsening in patients with pulmonary hypertension due to interstitial lung disease 2025 ·JHLT Open ·Karim El‐Kersh, Remzi Bag, Neel S. Bhatt, Christopher S. King, Aaron B. Waxman, Franz Rischard, Hyun Kim, David Cella, Eric Shen, (unknown)	0
3	A Bridge to Somewhere: VA-ECMO as a Bridge to Recovery in Pulmonary Arterial Hypertension 2025 ·American Journal of Respiratory and Critical Care Medicine ·(unknown), C. Thomas, (unknown), Shambhu Aryal, (unknown), (unknown), Christopher S. King, (unknown), (unknown), (unknown)	0
4	Delayed Presentation of Hyperammonemia Syndrome After Lung Transplant 2024 ·The Journal of Heart and Lung Transplantation ·James D. Wilkinson, (unknown), Sajal D. Tanna, (unknown), C. Thomas, (unknown), Vikramjit Khangoora, Oksana A. Shlobin, Steven D. Nathan, Shambhu Aryal, Christopher S. King	0
5	Pulmonary vascular dysfunction without pulmonary hypertension: A distinct phenotype in idiopathic pulmonary fibrosis 2024 ·Pulmonary Circulation ·Steven D. Nathan, (unknown), Qiong Zhao, (unknown), Dennis Kim, (unknown), (unknown), (unknown), (unknown), Vikramjit Khangoora, Oksana A. Shlobin, Christopher Thomas, (unknown), Christopher S. King, Abhimanyu Chandel	3
6	Antithrombotic Therapy for VTE Disease breakdown → 2024 ·CHEST Journal ·Scott M. Stevens, Scott C. Woller, Lisa Baumann Kreuziger, Kevin C. Doerschug, Geert‐Jan Geersing, Frederikus A. Klok, Christopher S. King, Susan Murin, Janine Vintch, Philip S. Wells, Suman Wasan, Lisa K. Moores	37
7	Hospitalization Rates in Interstitial Lung Disease: An Analysis of the Pulmonary Fibrosis Foundation Registry 2024 ·American Journal of Respiratory and Critical Care Medicine ·Christopher S. King, Rosalinda V. Ignacio, Vikramjit Khangoora, (unknown), (unknown), (unknown), (unknown), Shambhu Aryal, Oksana A. Shlobin, Kevin R. Flaherty, Joseph A. Lasky, Steven D. Nathan	3
8	Derivation and validation of a noninvasive prediction tool to identify pulmonary hypertension in patients with IPF: Evolution of the model FORD 2023 ·The Journal of Heart and Lung Transplantation ·Steven D. Nathan, Abhimanyu Chandel, Ya Wang, (unknown), Lixin Shao, Timothy R. Watkins, (unknown), Christopher S. King, (unknown)	12
9	How long is too long: A retrospective study evaluating the impact of the duration of noninvasive oxygenation support strategies (high flow nasal cannula & BiPAP) on mortality in invasive mechanically ventilated patients with COVID-19 2023 ·PLoS ONE ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Brian Lam, Maria Stepanova, Linda Henry, Christopher S. King, Mehul Desai	2
10	Factors associated with listing for lung transplantation in IPF patients: An analysis of the pulmonary fibrosis foundation registry 2023 ·Heliyon ·Christopher S. King, Emily White, Shambhu Aryal, Oksana A. Shlobin, (unknown), Anne Brown, Christopher Thomas, Vikramjit Khangoora, (unknown), Kevin R. Flaherty, Steven D. Nathan, Joshua J. Mooney	2
11	Prevalence of pulmonary hypertension in patients with COVID‐19 related lung disease listed for lung transplantation: A UNOS registry analysis 2023 ·Pulmonary Circulation ·(unknown), Abhimanyu Chandel, Christopher S. King, Shambhu Aryal, Anne Brown, Vikramjit Khangoora, (unknown), (unknown), (unknown), Oksana A. Shlobin, Steven D. Nathan	2
12	Connective tissue disease‐associated pulmonary hypertension: A comprehensive review 2023 ·Pulmonary Circulation ·Vikramjit Khangoora, Elana J. Bernstein, Christopher S. King, Oksana A. Shlobin	13
13	Association of D-dimer and Fibrinogen With Hypercoagulability in COVID-19 Requiring Extracorporeal Membrane Oxygenation 2021 ·Journal of Intensive Care Medicine ·Abhimanyu Chandel, (unknown), (unknown), (unknown), Vikramjit Khangoora, Christopher S. King	24
14	Impact of the new definition for pulmonary hypertension in patients with lung disease: an analysis of the United Network for Organ Sharing database 2021 ·Pulmonary Circulation ·Steven D. Nathan, Scott D. Barnett, Christopher S. King, Steeve Provencher, Joan Albert Barberà, Jean Pastré, Oksana A. Shlobin, Werner Seeger	21
15	Agreement Between the TEG 6s and TEG 5000 Analyzers in Extracorporeal Membrane Oxygenation 2021 ·ASAIO Journal ·Abhimanyu Chandel, Mehul Desai, Christopher S. King, (unknown), Anika Raja, Ramesh Singh, Heidi J. Dalton	4
16	Incidence and prognostic significance of pleural effusions in pulmonary arterial hypertension 2021 ·Pulmonary Circulation ·Abhimanyu Chandel, (unknown), (unknown), Vikramjit Khangoora, Steven D. Nathan, Kareem Ahmad, Shambhu Aryal, (unknown), (unknown), Anne Brown, Oksana A. Shlobin, Christopher S. King	5
17	Outcomes of mechanically ventilated patients with COVID-19 associated respiratory failure 2020 ·PLoS ONE ·Christopher S. King, (unknown), Alison Brown, (unknown), (unknown), Erik Osborn, Mehul Desai, Svetolik Djurkovic, (unknown), (unknown), James Lantry, Oksana A. Shlobin, Kareem Ahmad, Vikramjit Khangoora, Shambhu Aryal, A.C. Collins, Alan M. Speir, Steven D. Nathan	68
18	Early postoperative management after lung transplantation: Results of an international survey 2017 ·Clinical Transplantation ·Christopher S. King, Vincent G. Valentine, (unknown), (unknown), Oksana A. Shlobin, Anne Brown, Ramesh Singh, (unknown), Steven D. Nathan	5
19	Management of Right Heart Failure in the Critically Ill 2014 ·Critical Care Clinics ·Christopher S. King, Christopher W. May, Jeffrey Williams, Oksana A. Shlobin	19
20	Identification and treatment of comorbidities in idiopathic pulmonary fibrosis and other fibrotic lung diseases 2013 ·Current Opinion in Pulmonary Medicine ·Christopher S. King, Steven D. Nathan	33

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact